PPARδ agonist
Cardarine
Cardarine after one dose: 50% at ~16 h, 25% at 32 h, 12.5% at 48 h.
Drawn from the half-life in the app's model, ~16 h. The model's figures
- Compound
- Cardarine
- Symbol
- GW
- Family
- SARMs
- Parts
- 13
- References
- 26
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
- 1Alzheimer's Drug Discovery Foundation, 2025
- 2Olson et al., 2012
- 3Sport Integrity Australia
- 4World Anti-Doping Agency, 2026
- 5US Anti-Doping Agency
- 6Sprecher et al., 2007
- 7Oliver et al., 2001
- 8US Food and Drug Administration, 2025
- 9Australian Department of Health and Aged Care, 2022
- 10Risérus U, 2008
- 11Ooi et al., 2011
- 12Krämer DK, 2007
- 13Serrano-Marco et al., 2012
Cardarine, also written GW501516 or GW1516, is an oral drug that activates the peroxisome proliferator-activated receptor delta (PPARδ).5,6 GlaxoSmithKline developed it for metabolic disorders, and Oliver and colleagues, with GlaxoSmithKline affiliations, described it in the Proceedings of the National Academy of Sciences in 2001 as "a potent and subtype-selective PPARdelta agonist".1,7 The US Anti-Doping Agency (USADA) writes: "Often advertised as a selective androgen receptor modulator (SARM), GW1516 is actually a peroxisome proliferated-activated receptor d (PPARd ) agonist".5 An FDA warning letter of 12 December 2025 lists "Cardarine GW501516" among products the recipient marketed as selective androgen receptor modulators.8
Sport Integrity Australia states that GW1516 "is not approved for therapeutic use in Australia or other countries".3 A report from the Alzheimer's Drug Discovery Foundation, updated in May 2025, states that its clinical development "was terminated due to a safety signal of possible cancer potentiation in a preclinical rodent study".1 The WADA 2026 Prohibited List names GW1516 and GW501516 as examples of PPARδ agonists in class S4.4.1, prohibited at all times.4 The Australian Poisons Standard of October 2022 lists cardarine in Schedule 10, "Substances of such danger to health as to warrant prohibition of sale, supply and use".9
A search of PubMed on 16 November 2026 for GW501516 or cardarine in the title or summary text, limited to the publication types randomized controlled trial or clinical trial, returned 6 records. Four of them report GW501516 given to people, in 2007, 2008, 2011 and 2012, for 2 to 12 weeks at 2.5 to 10 mg a day.6,10,11,2 The other two, by Krämer and colleagues and by Serrano-Marco and colleagues, were laboratory studies of human muscle cells or adipocytes.12,13
How it works
In people
In the 2008 Diabetes trial, Risérus and colleagues gave 10 mg of GW501516 once daily for 2 weeks to 6 healthy, moderately overweight men and reported that the share of exhaled carbon dioxide coming directly from the fat in a test meal increased (P < 0.05) and that skeletal muscle expression of carnitine palmitoyl-transferase 1b (CPT1b) was significantly increased.10 The authors wrote: "The effect is probably caused by increased fat oxidation in skeletal muscle".10 In 24 healthy volunteers, Sprecher and colleagues reported that triglyceride clearance after fat feeding improved on GW501516 (P=0.02).6 In 13 men with dyslipidaemia and central obesity, Ooi and colleagues reported that 2.5 mg a day for 6 weeks decreased VLDL-apoB concentrations by increasing its fractional catabolism, and decreased apoC-III by lowering its production rate (P < 0.05).11
In cells and animals
Sprecher and colleagues treated human skeletal muscle cells with GW501516 in the laboratory, which induced fatty acid oxidation and raised CPT1 and CD36 expression, with a 2-fold increase in ABCA1 (P=0.002); LpL expression remained unchanged.6 In primary cultured human muscle cells, Krämer and colleagues (Journal of Biological Chemistry, 2007) found that GW501516 induced AMP-activated protein kinase (AMPK) phosphorylation and that the increase in fatty acid oxidation depended on both PPARδ and AMPK.12 In insulin-resistant, middle-aged, obese rhesus monkeys, Oliver and colleagues reported "a dramatic dose-dependent rise in serum high density lipoprotein cholesterol" while small-dense LDL, fasting triglycerides and fasting insulin fell.7 In vervet monkeys (4 groups of 6), Wallace and colleagues (Journal of Lipid Research, 2005) reported a maximum HDL-cholesterol rise from baseline of 43% on GW501516 against 5% on vehicle, with no statistically significant change in body weight, total cholesterol, triglycerides, VLDL-C, LDL-C or apoB.14 In a treadmill test in mice, Narkar and colleagues (Cell, 2008) reported that a "PPARbeta/delta agonist and exercise training synergistically increase oxidative myofibers and running endurance in adult mice".15 A 2014 review states that this Salk Institute team's 2008 article concerned GW501516 and AICAR in laboratory animals.16
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~16 h
- Bioavailability
- 95%
- Typical dose
- 10–20 mg/day
- Route
- Oral
- Time to peak
- ~2 h
| Parameter | App's figure | What the sources state |
|---|---|---|
| Half-life | ~16 hours | The app's figure. A half-life is not given in GlaxoSmithKline's study report of January 2008 or in the registry entries for its trials, and the registry entry for its 12-week study lists population pharmacokinetics (oral clearance and apparent volume of distribution) as a secondary outcome without values.17,18 |
| Bioavailability (oral) | ~95% | The app's figure. An oral bioavailability figure is not given in the study report or the registry entries cited here.17,18 |
| Time to peak | ~2 hours | The app's figure. A time to peak is not given in the study report or the registry entries cited here.17,18 |
| Route | Oral | GlaxoSmithKline's 12-week study dispensed tablets to take by mouth once a day in the morning.17 |
| Typical dose | 10–20 mg/day | The app's figure. The highest dose in the trials cited here is 10 mg once daily; 20 mg a day is not among the doses they report.17,2 |
A search of PubMed on 16 November 2026 for GW501516, GW1516 or cardarine with pharmacokinetic, half-life or metabolite in the title or summary text returned 30 records. The summaries of the four published trials (Sprecher, Risérus, Ooi, Olson) give no half-life, time to peak or bioavailability.6,10,11,2 The chart below draws a curve from the app's half-life of about 16 hours and time to peak of about 2 hours, with the once-daily schedule used in GlaxoSmithKline's 12-week study.17
Level over 5 days
Level, as a share of the peak after one 10 mg dose
As studied: every day17.
An illustration from a pharmacokinetic model using a half-life of 16 hours. It is not a measured level or a suggested dose.
Thevis and colleagues (Methods in Molecular Biology, 2013) used human liver microsomal preparations to obtain "minute amounts of possible urinary metabolites", synthesised the most abundant products, and built a urine assay for GW1516 and two oxidized metabolites using liquid chromatography-tandem mass spectrometry.19
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Sprecher and colleagues, 20076 | Randomised, placebo-controlled, in hospital and sedentary; first author listed with GlaxoSmithKline | 24 healthy volunteers (placebo 6, 2.5 mg 9, 10 mg 9) | 2.5 or 10 mg once daily by mouth, 2 weeks | Triglycerides trended down (P=0.08 at 10 mg); triglyceride clearance after fat feeding improved (P=0.02); HDL cholesterol was higher on both doses against an 11.5% decrease on placebo. |
| Risérus and colleagues, 200810 | Randomised, double-blind, three parallel groups (GW501516, a PPARα comparator, placebo); no sponsor stated in the source text | 18 healthy, moderately overweight men, 6 per group | 10 mg once daily, 2 weeks (comparator 20 micrograms once daily) | On GW501516: fasting triglycerides -30%, apoB -26%, LDL cholesterol -23%, insulin -11%, HDL cholesterol unchanged, liver fat -20% (P<0.05), urinary isoprostanes -30% (P=0.01). On the comparator only triglycerides fell (-30%). |
| Ooi and colleagues, 201111 | Randomised, double-blind, crossover; University of Western Australia; no sponsor stated in the source text; author list includes Sprecher, listed with GlaxoSmithKline in Sprecher and colleagues, 2007 | 13 men with dyslipidaemia and central obesity | 2.5 mg a day, two 6-week periods with a 2-week placebo washout | Plasma triglycerides, fatty acid, apoB-100 and apoB-48 fell; HDL cholesterol, apoA-II and LpA-I:A-II rose (P < 0.05 for the kinetic changes). |
| Olson and colleagues, 20122 | Randomised, placebo-controlled, multicentre; first author listed with GlaxoSmithKline | 268 people with HDL cholesterol below 1.16 mmol/L; a second exploratory study of 37 | 2.5, 5.0 or 10.0 mg for 12 weeks; the second study used 5 then 10 mg | Changes from baseline: HDL cholesterol up to +16.9% (10 mg), apoA-I up to +6.6%; LDL cholesterol -7.3%, triglycerides -16.9%, apoB -14.9%, free fatty acids -19.4% (no dose given for these four). |
| GlaxoSmithKline study report PAD20001, 200817 | Randomised, double-blind, placebo-controlled, two stages, 51 centres in 12 European countries; sponsor GlaxoSmithKline | 283 randomised (placebo 84, 2.5 mg 50, 5 mg 86, 10 mg 63), aged 18 to 75 with low HDL cholesterol | 2.5, 5 or 10 mg once daily, 12 weeks | HDL cholesterol rose over placebo by 13.3% at 10 mg (95% CI 7.6 to 18.9; p<0.001), 9.3% at 2.5 mg and 8.1% at 5 mg; triglycerides fell 29.2% and weight rose 1.74 kg more than placebo at 10 mg. |
| GlaxoSmithKline registry entry NCT0038818020 | Randomised, double-blind, parallel group (official title; the entry lists its study type as observational); sponsor GlaxoSmithKline | 71 enrolled; men aged 18 to 55 with body mass index 27 to 43 | 10 mg of GW501516X for 12 weeks (comparator 20 micrograms of GW590735X) | No results are posted in the entry; the primary outcome listed is body fat levels. |
Deeper analysis: Sprecher and colleagues, 2007
Sprecher and colleagues (Arteriosclerosis, Thrombosis, and Vascular Biology, 2007) gave placebo (n=6), 2.5 mg (n=9) or 10 mg (n=9) once daily by mouth to healthy volunteers who were in hospital and sedentary for 2 weeks.6 Standard lipids and lipoproteins were measured and fat feeding studies were run.6 Serum triglycerides trended down (P=0.08 at 10 mg), triglyceride clearance after fat feeding improved (P=0.02), and HDL cholesterol was higher on both doses than the 11.5% decrease on placebo.6 The authors called it "the first report of a PPARdelta agonist administered to man" and described it as a "small study".6 The first author is listed with GlaxoSmithKline, and no funder is stated in the source text, which also gives no adverse event figures.6
Deeper analysis: Risérus and colleagues, 2008
Risérus and colleagues (Diabetes, 2008) compared 10 mg of GW501516 once daily, a PPARα comparator and placebo, 6 healthy, moderately overweight men per group, for 2 weeks.10 GW501516 lowered fasting triglycerides by 30%, apoB by 26%, LDL cholesterol by 23% and insulin by 11% and left HDL cholesterol unchanged, and the authors concluded it "reverses multiple abnormalities associated with the metabolic syndrome without increasing oxidative stress".10 No sponsor and no limitations are stated in the source text; the author list includes Sprecher, who is listed with GlaxoSmithKline in Sprecher and colleagues, 2007.10,6
Deeper analysis: GlaxoSmithKline's 12-week dose-ranging study
GlaxoSmithKline's report on study PAD20001, dated January 2008, describes two stages at 51 centres in 12 European countries, each with a 2-week placebo run-in and 12 weeks of double-blind treatment.17 After an interim analysis the planned total fell from approximately 424 to 290, and 283 people were randomised; 262 (90%) completed, and 3 (1%) withdrew because of adverse events.17 Olson and colleagues (Arteriosclerosis, Thrombosis, and Vascular Biology, 2012), whose first author is listed with GlaxoSmithKline, report a 12-week study of 2.5, 5.0 or 10.0 mg or placebo in 268 patients with HDL cholesterol below 1.16 mmol/L, plus an exploratory study of 37.2 The report states "Publication(s): None at the time of this report" and counts 283 randomised, the Olson paper counts 268, and the registry entry gives an enrolment of 424; neither the report nor the registry entry names the paper.17,2,18 The official title of the registry entry describes three stages, a fenofibrate comparator and eight weeks of treatment, where the report describes two stages and 12 weeks, and NCT00388180 lists the Olson paper as a derived reference.18,17,20 HDL cholesterol rose over placebo by 13.3% at 10 mg, LDL cholesterol fell 11.2% at 10 mg and triglycerides fell 29.2%, while hsCRP gave "an inconsistent response" not significantly different from placebo and insulin fell, with a significant difference from placebo listed at 2.5 mg (-18.2%) and 5 mg (-14.1%).17 The report states: "The long term clinical relevance of these findings is currently difficult to ascertain", which "would need to be further explored in outcome based trials", and that the size of the response "may be dependent upon baseline lipid characteristics".17 The registry lists GlaxoSmithKline as the sponsor of study PAD20001, and the source text of the paper states no funder and no limitations.18,2
The outcomes these papers report are blood lipids and lipoproteins, insulin, liver fat and fat oxidation markers, in groups of 13 to 283 people over 2 to 12 weeks.6,10,11,2 The 6-week crossover trial of Ooi and colleagues listed the University of Western Australia as its lead sponsor and the National Heart Foundation, Australia as a collaborator in the registry.21
Doses reported in studies and on labels
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Sprecher and colleagues, 2007 | 2.5 or 10 mg | Once daily | 2 weeks |
| Risérus and colleagues, 2008 | 10 mg (comparator 20 micrograms) | Once daily | 2 weeks |
| Ooi and colleagues, 2011 | 2.5 mg | Per day | 6 weeks, with 2-week placebo washout |
| Olson and colleagues, 2012 | 2.5, 5.0 or 10.0 mg | Not stated in the source text | 12 weeks; second study 5 and 10 mg in sequence |
| GlaxoSmithKline study report PAD20001, 2008 | 2.5, 5 or 10 mg | Once daily, in the morning | 12 weeks |
| GlaxoSmithKline registry entry NCT00388180 | 10 mg | Not stated in the source text | 12 weeks |
Side effects reported
In GlaxoSmithKline's 12-week study, any adverse event was reported by 57% on placebo, 64% on 2.5 mg, 60% on 5 mg and 47% on 10 mg, and headache of any cause by 16%, 18%, 16% and 9%.17 The report names headache as the most common drug-related adverse event.17 Fatigue was reported by 7 of 50 people (14%) on 2.5 mg against 2 of 86 (2%) on placebo, and myalgia by 5 of 88 (6%) on 5 mg against 2 of 86 (2%).17 Four serious adverse events were reported on therapy: pyrexia on placebo, myocardial infarction and appendicitis on 2.5 mg, and chest pain on 10 mg; only the pyrexia was assessed as drug-related by the investigator.17 No deaths occurred, and 3 people (1%) withdrew because of adverse events: one each on 2.5 mg, 5 mg and 10 mg.17 Weight rose in a dose-related way, by 1.74 kg more than placebo at 10 mg (95% CI 0.70 to 2.78; p=0.001), and the report found no clinically significant change from baseline in hematology and clinical chemistry parameters.17 The report's summary states that GW501516 at 2.5, 5 and 10 mg "was well tolerated during the study".17
The ADDF report states that clinical development "was terminated due to a safety signal of possible cancer potentiation in a preclinical rodent study".1 In its discussion of PPARδ agonists as a class, the report says the termination "may not necessarily be a class effect" and that "at this point there isn't evidence to indicate that PPARδ agonists are themselves tumorigenic".1 WADA's alert of March 2013, as quoted by The Conversation, called GW501516 "a developmental drug that was withdrawn from research by the pharmaceutical company and terminated when serious toxicities were discovered in pre-clinical studies".22 Sport Integrity Australia states that "Various adverse effects have been documented in both clinical trials and case reports" and that GW1516 "is associated with high frequency of carcinogenicity and reproductive toxicity", and a 2024 case report states that "Clinical trials with GW1516 were discontinued when animal studies demonstrated carcinogenic effects".3,23 USADA acknowledges that sellers argue "animals were given large doses of this compound" and writes: "Animals are given large doses for a short time to see if they get sick".5 USADA states that GW1516 was pulled from clinical trials over a cancer finding and "has not undergone human studies", which differs from the human trials above.5
In mice, Wang and colleagues (Proceedings of the National Academy of Sciences, 2006) reported that deleting PPARδ "decreases intestinal adenoma growth in Apc(Min/+) mice and inhibits tumor-promoting effects of a PPARdelta agonist GW501516", and that PPARδ activation up-regulated VEGF in colon carcinoma cells.24 In mice, Pollock and colleagues (PLoS One, 2011) reported that wild-type and PDK1-transgenic mice treated with GW501516 "exhibited accelerated rates of tumor formation", more pronounced in the transgenic animals.25 In five human cancer cell lines, Hollingshead and colleagues (Carcinogenesis, 2007) reported that neither GW0742 nor GW501516 increased cell growth or Akt phosphorylation, and VEGF or COX2 expression did not rise in the cell lines or in the liver, colon and colon polyps of mice given the ligands.26 Billin and Willson, two of the authors of Hollingshead and colleagues, are also named authors of Sprecher and colleagues, 2007, whose first author is listed with GlaxoSmithKline.26,6 These are mouse and cell results, and they point in different directions.24,25,26
Bloodwork and markers
Sources in this part
HDL cholesterol was the primary outcome of the 12-week study, rising over placebo by 13.3% at 10 mg, 9.3% at 2.5 mg and 8.1% at 5 mg, while in the 2-week trial of Risérus and colleagues at 10 mg HDL cholesterol was unchanged.17,10 In the same 12-week study LDL cholesterol fell 5.7% at 5 mg and 11.2% at 10 mg, total cholesterol fell 6.6% and 10.6%, and fibrinogen fell 10.9% and 17.3% against placebo.17 Risérus and colleagues reported liver fat 20% lower (P < 0.05) after 2 weeks at 10 mg.10 Thevis and colleagues describe a urine assay for GW1516 and two oxidized metabolites by liquid chromatography-tandem mass spectrometry, tested on spiked urine samples.19
Regulatory and anti-doping status
The WADA 2026 Prohibited List, in effect from 1 January 2026, names GW1516 and GW501516 as examples of PPARδ agonists in class S4.4.1, a metabolic modulator class prohibited at all times, in and out of competition.4 Substances in classes S4.3 and S4.4 are non-Specified Substances.4 A 2014 review states that WADA added GW501516 and AICAR to the Prohibited List in 2009.16 Sport Integrity Australia states that a Therapeutic Use Exemption would not be granted for GW1516, and that in 2023 there were 54 adverse analytical findings for it, 17% of all those in section S.4.3 A 2024 case report states that 139 adverse analytical findings involving GW1516 have been reported to WADA since 2009, from 1 (2012) to 31 (2016) a year and 1–12% of class S4 cases, ranges that do not include the 2023 figures above (54 findings, 17%).23
The Australian Poisons Standard of October 2022 lists cardarine in Schedule 10, "Substances of such danger to health as to warrant prohibition of sale, supply and use", and Sport Integrity Australia states that the TGA lists GW1516 under Schedule 10.9,3 FDA's warning letter of 12 December 2025 to Dynamic Health Group dba SARMS AMERICA states that products the firm marketed as SARMs, including "Cardarine GW501516", are "unapproved new drugs under section 505(a)" of the Federal Food, Drug, and Cosmetic Act.8 USADA states that "GW1516 is not legally permitted in any medications, supplements, or foods".5
What is not known
A search of PubMed on 16 November 2026 for GW501516 or cardarine in the title or summary text returned 320 records. ClinicalTrials.gov returned 3 entries for GW501516 on the same date, two sponsored by GlaxoSmithKline and one by the University of Western Australia. A half-life, time to peak and oral bioavailability are not given in the study report or registry entries cited here, so the app's figures of about 16 hours, about 2 hours and 95% are not matched by a figure from the study report or those entries.17,18,20,21 The longest human trial cited ran 12 weeks, and the GlaxoSmithKline report says the long-term clinical relevance of its findings is difficult to ascertain.17 The ADDF report names an Apc(min) mouse model of intestinal cancer as the study after which clinical development ended and gives 300 mg/kg as a rodent dose associated with toxicity, while WADA's alert, as quoted by The Conversation, says only "serious toxicities" and gives no doses or tumour types.1,22 The registry entry NCT00388180 lists body fat as its primary outcome and posts no results.20
Frequently asked questions
Sources in this part
- 1Alzheimer's Drug Discovery Foundation, 2025
- 2Olson et al., 2012
- 3Sport Integrity Australia
- 4World Anti-Doping Agency, 2026
- 5US Anti-Doping Agency
- 6Sprecher et al., 2007
- 8US Food and Drug Administration, 2025
- 9Australian Department of Health and Aged Care, 2022
- 10Risérus U, 2008
- 17GlaxoSmithKline, 2008
- 18GlaxoSmithKline
- 22The Conversation, 2013
What is Cardarine (GW501516)?
What is the half-life of Cardarine?
The app's figure for the half-life of Cardarine is about 16 hours, and no human half-life is given in the study report or registry entries cited here.17,18 The registry entry for GlaxoSmithKline's 12-week study lists population pharmacokinetics, including oral clearance and apparent volume of distribution, as a secondary outcome without values.18
Is Cardarine banned by WADA?
Is Cardarine approved by the FDA?
FDA's warning letter of 12 December 2025 to one firm, Dynamic Health Group dba SARMS AMERICA, calls the products that firm marketed as SARMs, including "Cardarine GW501516", unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act.8 Sport Integrity Australia states that GW1516 is not approved for therapeutic use in Australia or other countries.3
Why did GlaxoSmithKline stop developing Cardarine?
What doses of Cardarine were used in human trials?
What did Cardarine do to cholesterol in trials?
Guides, tools and comparisons
References
- Alzheimer's Drug Discovery Foundation. Cognitive Vitality Reports: Seladelpar (PPARδ Agonists). Last updated 12 May 2025. ADDF report
- Olson EJ, et al. Lipid effects of PPAR-delta agonist GW501516 in subjects with low HDL cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol 2012. PMID 22814748
- Sport Integrity Australia. GW1516 (GW501516) information. n.d. Sport Integrity Australia
- World Anti-Doping Agency. Prohibited List 2026, in effect from 1 January 2026. WADA list
- US Anti-Doping Agency. What should tested athletes know about GW1516? USADA
- Sprecher DL, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 2007. PMID 17110604
- Oliver WR Jr, et al. A selective PPARdelta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001. PMID 11309497
- US Food and Drug Administration. Warning letter 719257 to Dynamic Health Group dba SARMS AMERICA, 12 December 2025. FDA warning letter
- Australian Department of Health and Aged Care. Poisons Standard October 2022 (Schedule 10). Poisons Standard
- Risérus U, et al. Activation of PPARdelta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008. PMID 18024853
- Ooi EM, et al. Mechanism of action of a PPAR-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab 2011. PMID 21816786
- Krämer DK, et al. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 2007. PMID 17500064
- Serrano-Marco L, et al. TNF-α inhibits PPARβ/δ activity and SIRT1 expression through NF-κB in human adipocytes. Biochim Biophys Acta 2012. PMID 22683888
- Wallace JM, et al. Effects of PPAR alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 2005. PMID 15716581
- Narkar VA, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008. PMID 18674809
- Pokrywka A, et al. Metabolic modulators of the exercise response: doping control analysis of GW501516 and AICAR. J Physiol Pharmacol 2014. PMID 25179079
- GlaxoSmithKline. Study PAD20001: GW501516 in subjects with low HDLc, clinical study report synopsis (EudraCT 2004-000882-36). EU Clinical Trials Register, January 2008. EU CTR result
- GlaxoSmithKline. GW501516 in subjects who have low level of high-density lipoprotein cholesterol. ClinicalTrials.gov NCT00158899. NCT00158899
- Thevis M, et al. Synthesis, mass spectrometric characterization, and analysis of the PPARdelta agonist GW1516 and its major human metabolites: targets in sports drug testing. Methods Mol Biol 2013. PMID 23100242
- GlaxoSmithKline. An exploratory study to look at the effect of two investigational drugs on body fat and inflammation. ClinicalTrials.gov NCT00388180. NCT00388180
- The University of Western Australia. Regulation of lipoprotein transport in metabolic syndrome. ClinicalTrials.gov NCT00841217. NCT00841217
- The Conversation. Anti-doping agency warns cheats on the health risks of Endurobol. 22 March 2013, updated 12 April 2013. The Conversation
- Breuer J, et al. Complementary information concerning the suspected interindividual transmission of GW1516, a substance prohibited in sport, through intimate contact: a case report. Forensic Toxicol 2024. PMC11269478
- Wang D, et al. Crosstalk between PPARdelta and VEGF stimulates cancer progression. Proc Natl Acad Sci USA 2006. PMID 17148604
- Pollock CB, et al. PPARδ activation acts cooperatively with PDK1 to enhance mammary tumorigenesis. PLoS One 2011. PMID 21297860
- Hollingshead HE, et al. PPARbeta/delta ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 2007. PMID 17693664